THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)
FF003G
APPENDIX 5 FORMS RELATING TO LISTING FORM F THE GROWTH ENTERPRISE MARKET (GEM) COMPANY INFORMATION SHEETCase Number:
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.
Company name: | Hong Kong Life Sciences and Technologies Group Limited |
Stock code (ordinary shares): | 8085 |
This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.
The information in this sheet was updated as of 6 January 2017
-
General
Place of incorporation:
Cayman Islands
Date of initial listing on GEM:
7 March 2002
Name of Sponsor(s):
N/A
Names of directors:
(please distinguish the status of the directors
- Executive, Non-Executive or Independent Non-Executive)
Executive Directors
Mr. David Lin Kao Kun (Vice Chairman) Mr. Lu Zhiqiang (Chief Executive Officer) Mr. Chui Kwong Kau
Mr. Jiang Hongqing Ms. Li Mei
Non-executive Director
Ms. Lam Kuo (Chairman)
Independent Non-executive Directors
Mr. Hung Yat Ming Mr. Chan Yun Hing
Mr. Gui Qiangfang
Name(s) of substantial shareholder(s): (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company
Name Number of Approximate ordinary shares percentage of
held issued share capital
Mr. David Lin Kao Kun 878,862,333 15.45%
Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company:
N/A
Financial year end date:
31 March
Registered address:
Cricket Square Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111 Cayman Islands
British West Indies
Head office and principal place of business:
Unit 2704, 27/F., West Tower Shun Tak Centre
168-200 Connaught Road Central
Hong Kong
Web-site address (if applicable):
www.hklifesciences.com
Share registrar:
Principal share registrar and transfer office in the Cayman Islands:
Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor, Royal Bank House
24 Shedden Road, George Town Grand Cayman KY1-1110 Cayman Islands
Branch share registrar and transfer office in Hong Kong:
Tricor Standard Limited Level 22, Hopewell Centre 183 Queen's Road East
Hong Kong
Auditors:
Pan-China (H.K.) CPA Limited
-
Business activities
The Company is an investment holding company. The Company and its subsidiaries are principally engaged in (i) anti-aging and stem cell technology businesses; (ii) trading business; (iii) money lending business; and (iv) securities investment.
-
Ordinary shares
Number of ordinary shares in issue:
5,688,396,805
Par value of ordinary shares in issue:
HK$0.04
Board lot size (in number of shares):
4,000
Name of other stock exchange(s) on which ordinary shares are also listed:
N/A
-
Warrants
Stock code:
N/A
Board lot size:
Expiry date:
Exercise price:
Conversion ratio:
(Not applicable if the warrant is denominated in dollar value of conversion right)
No. of warrants outstanding:
No. of shares falling to be issued upon
the exercise of outstanding warrants:
- Other securities
Details of any other securities in issue.
N/A
If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.
N/A
Responsibility statementThe directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.
The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.
The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.
Signed: | |
(Sd.) | (Sd.) |
Lam Kuo | David Lin Kao Kun |
(Sd.) | (Sd.) |
Lu Zhiqiang | Chui Kwong Kau |
(Sd.) | (Sd.) |
Jiang Hongqing | Li Mei |
(Sd.) | (Sd.) |
Hung Yat Ming | Chan Yun Hing |
(Sd.) | |
Gui Qiangfang |
NOTES
This information sheet must be signed by or pursuant to a power of attorney for and on behalf of each of the Directors of the Company.
Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet, together with a hard copy duly signed by or on behalf of each of the Directors, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.
Please send a copy of this form by facsimile transaction to Hong Kong Securities Clearing Company Limited (on 2815-9353) or such other number as may be prescribed from time to time) at the same time as the original is submitted to the Exchange.
Hong Kong Life Sciences and Technologies Group Limited published this content on 06 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 January 2017 10:37:04 UTC.
Original documenthttp://www.hklifesciences.com/docs/GLN20170106065.pdf
Public permalinkhttp://www.publicnow.com/view/5A6B9D6752098C535BC9298CE8416A999DA4B561